Search

Your search keyword '"Vincze, Aron"' showing total 178 results

Search Constraints

Start Over You searched for: Author "Vincze, Aron" Remove constraint Author: "Vincze, Aron"
178 results on '"Vincze, Aron"'

Search Results

1. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years

2. Detailed Characteristics of Post-discharge Mortality in Acute Pancreatitis

3. Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study

5. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

6. Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab – A prospective, multicenter cohort from Hungary

7. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

8. Efficacy, drug sustainability, and safety of ustekinumab treatment in Crohn’s disease patients over three years

9. Glucose levels show independent and dose-dependent association with worsening acute pancreatitis outcomes: Post-hoc analysis of a prospective, international cohort of 2250 acute pancreatitis cases

12. Early occurrence of pseudocysts in acute pancreatitis – A multicenter international cohort analysis of 2275 cases

14. Acid suppression therapy, gastrointestinal bleeding and infection in acute pancreatitis – An international cohort study

15. Development of disturbance of consciousness is associated with increased severity in acute pancreatitis

16. Hypertriglyceridemia-induced acute pancreatitis: A prospective, multicenter, international cohort analysis of 716 acute pancreatitis cases

17. EarLy Elimination of Fatty Acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial): Protocol of an open-label, multicenter, adaptive randomized clinical trial

21. Outcomes and timing of endoscopic retrograde cholangiopancreatography for acute biliary pancreatitis

22. Antibiotic therapy in acute pancreatitis: From global overuse to evidence based recommendations

23. Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab.

24. Genetic analysis of the bicarbonate secreting anion exchanger SLC26A6 in chronic pancreatitis

26. Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

27. Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study

29. EASY-APP: An artificial intelligence model and application for early and easy prediction of severity in acute pancreatitis

30. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

32. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study

34. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

35. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

36. Investigating the early phase of chronic pancreatitis: the Goulash-Plus trial protocol and the results of the first 10 months

37. Outcomes and timing of endoscopic retrograde cholangiopancreatography for acute biliary pancreatitis

40. A Multicenter, International Cohort Analysis of 1435 Patients to Support Clinical Trial Design in Acute Pancreatitis

41. Disturbance of consciousness is associated with higher severity and mortality of acute pancreatitis

42. Mo1892 – Non-Medical Reverse Switch Between the Originator Infliximab and Its Biosimilar in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Therapeutic Drug Monitoring

44. Bidirectional Relationship Between Reduced Blood pH and Acute Pancreatitis: A Translational Study of Their Noxious Combination

45. Mo1843 - Non-Medical Mandatory Reversed and Back and Forth Switch Between Infliximab and its Biosimilar: Early Clinical Outcomes

46. Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis

48. Misinterpretation of C reactive protein level and white blood cell count are behind the overuse of antibiotics in acute pancreatitis

49. Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

50. Final Results on Efficacy and Safety of Biosimilar Infliximab after One-Year: Results from a Prospective Nationwide Cohort

Catalog

Books, media, physical & digital resources